Bayer, a life science company with focus in health care and agriculture has paid $400 million and committed to over $1 billion to buy into Loxo Oncology’s tropomyosin receptor kinase (TPK) inhibitor franchise. Loxo’s drug, has had a 75% success rate in its midphase trial. This decision was made so that the drug would reach more patients more quickly. To read more about the new commitment, click here.